BBIO Earning Date, Earning Analysis and Earning Prediction
Earning Analysis
Welcome to our in-depth analysis of BridgeBio Pharma Inc(BBIO) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of BridgeBio Pharma Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
Name
EPS
Revenue
Price Reaction
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q3
2025-10-29
After Hours
-0.88
-0.95
-7.95
106.05M
120.70M
+13.81
-4.88
-7.88
FY2025Q2
2025-08-05
After Hours
-0.64
-0.95
-48.44
88.78M
110.57M
+24.54
-8.94
-1.97
FY2025Q1
2025-04-29
After Hours
-1.00
-0.88
+12.00
57.72M
116.63M
+102.06
+5.33
+4.94
FY2024Q4
2025-02-20
Pre-Market
-1.09
-1.40
-28.44
4.04M
5.88M
+45.62
+1.42
-7.83
FY2024Q2
2024-08-01
-
-1.09
-1.02
+6.42
4.48M
2.17M
-51.55
+0.89
-7.82
FY2024Q1
2024-05-02
-
-0.40
-0.05
+87.50
83.78M
211.12M
+152.00
+2.63
+2.48
FY2023Q4
2024-02-22
-
-0.95
-0.96
-1.05
3.79M
1.75M
-53.96
-1.64
+3.31
FY2023Q3
2023-11-02
-
-0.86
-1.08
-25.58
4.49M
4.09M
-8.80
+1.01
+10.28
FY2023Q2
2023-08-03
-
-0.86
-0.98
-13.95
2.99M
1.64M
-45.18
+0.31
-1.03
-
2023-05-04
-
-0.84
-0.92
-9.52
-
-
-
-6.25
-3.96
BBIO Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, BridgeBio Pharma Inc reported performance for FY2025Q3, announced on 2025-10-29. The company achieved an EPS of -0.95, compared to analyst estimates of -0.88 by -7.95% . Revenue for the quarter reached 120.70M compared to expectations of 106.05M by 13.81% .
The stock price reacted with a -4.88% one-day change and a -7.88% five-day change following the earnings release. These movements reflect market reaction in BridgeBio Pharma Inc growth trajectory and strategic initiatives.
BBIO Earnings Forecast
Looking ahead, BridgeBio Pharma Inc(BBIO) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 148.15M and an EPS of -0.66.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been Revise Upward by 5.64%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 14.96% . These revisions correlate with a 44.71% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in BridgeBio Pharma Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between BBIO's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+5.64%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
+14.96%
In Past 3 Month
Stock Price
Go Up
+44.71%
In Past 3 Month
1Y
3Y
5Y
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:473.04M
--
EPS Estimate-Annual FY 2025:-3.45
—
Stock Price74.51
BBIO Revenue and EPS Performance: A Historical Perspective
BridgeBio Pharma Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-29,After Hours):
EPS: -0.95 (Actual) vs.-0.88 (Estimate) (-7.95%)
Revenue: 120.70M (Actual) vs. 106.05M (Estimate) (13.81%)
Price Reaction:-4.88%(1-Day), -7.88%(5-Day)
FY2025Q2 (2025-08-05,After Hours):
EPS: -0.95 (Actual) vs.-0.64 (Estimate) (-48.44%)
Revenue: 110.57M (Actual) vs. 88.78M (Estimate) (24.54%)
Price Reaction:-8.94%(1-Day), -1.97%(5-Day)
FY2025Q1 (2025-04-29,After Hours):
EPS: -0.88 (Actual) vs.-1.00 (Estimate) (12.00%)
Revenue: 116.63M (Actual) vs. 57.72M (Estimate) (102.06%)
Price Reaction:5.33%(1-Day), 4.94%(5-Day)
Earnings Reaction
The chart below shows how BBIO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BBIO sees a -2.45% change in stock price 10 days leading up to the earnings, and a -2.65% change 10 days following the report. On the earnings day itself, the stock moves by +0.62%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -4.88% on the day following the earnings release and then changed by -0.60% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
People Also Watch
Frequently Asked Questions
What were the key highlights of BBIO's latest earnings report for FY2025Q3?
BBIO reported its FY2025Q3 earnings on 2025-10-29, showcasing a revenue of 120.70M against an estimate of 106.05M, resulting in a 13.81% surprise. The EPS was -0.95, surpassing the expected -0.88 by -7.95% . The stock experienced a -4.88% price change on the earnings day and a -7.88% change over the next five days, reflecting market reactions to the results.
How did BBIO's stock price react after the FY2025Q3 earnings release?
Following BBIO's FY2025Q3 earnings announcement on 2025-10-29, the stock price moved by -4.88% on the day of the release. Over the subsequent five days, it saw a -7.88% change. Historically, BBIO's stock price tends to shift by an average of -2.45% in the 10 days leading up to earnings and -2.65% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for BBIO for 2025/Q4?
For 2025/Q4, analysts estimate BBIO’s annual revenue to reach 148.15M, while the EPS is projected at -0.66. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 14.96% over the past three months, indicating analyst expectation in the company’s performance.
How does BBIO's stock price correlate with earnings forecast revisions?
The correlation between BBIO's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 14.96% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from BBIO's next earnings report?
Based on historical trends, BBIO's stock price typically moves by -2.45% in the 10 days before its earnings and -2.65% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.66 and revenue of 148.15M.
What is the sentiment in BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Summary?
The earnings call highlights strong revenue growth, promising product development, and a robust cash position. Despite increased expenses, the company maintains significant cash reserves. The Q&A reveals positive sentiment towards market dynamics and strategic positioning, with growth in patient share and prescriber engagement. Management's confidence in product efficacy and market potential further supports a positive outlook. The market cap indicates a moderate reaction, suggesting a stock price increase in the range of 2% to 8% over the next two weeks.
